Can I Take St. John's Wort with Accutane (Isotretinoin)?

The Short Answer: Avoid This Combination

The combination of St. John's Wort and isotretinoin is not considered safe from a drug-interaction standpoint. St. John's Wort induces the same metabolic enzymes that process isotretinoin, meaning your body may clear the drug faster, resulting in lower-than-intended blood levels. For a medication dosed carefully to achieve remission in severe acne, any reduction in exposure can translate directly to treatment failure.

Isotretinoin is already one of the most tightly regulated drugs in the United States. The iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program, mandated by the FDA, requires monthly prescriber attestation, two forms of contraception for people who can become pregnant, and monthly pregnancy testing precisely because the drug is a known human teratogen at therapeutic doses. Adding a supplement that unpredictably lowers drug concentrations introduces a layer of pharmacological uncertainty that the program was not designed to accommodate.

Why Prescribers Often Miss Herbal Supplements

Herbal products are purchased over the counter, and patients rarely volunteer that information during clinic visits. A 2019 survey published in JAMA Internal Medicine found that 34% of adults using prescription medications also used herbal supplements, but fewer than one-third disclosed that to their clinician (1). St. John's Wort is among the top-selling herbal products in the United States, often marketed for low mood and mild anxiety. Patients on isotretinoin may reach for it precisely because isotretinoin itself carries an FDA label warning about possible depression.

How St. John's Wort Affects Drug Metabolism

St. John's Wort contains two classes of active compounds: hypericin and pseudohypericin (naphthodianthrones) and hyperforin (a phloroglucinol derivative). Hyperforin is the principal driver of the drug-interaction concern. It activates the pregnane X receptor (PXR), a nuclear receptor that functions as a transcription factor for several cytochrome P450 enzymes and drug transporters.

CYP3A4 Induction

The CYP3A4 enzyme metabolizes roughly 50% of all marketed drugs. Hyperforin-mediated PXR activation upregulates CYP3A4 expression in the intestinal wall and the liver, increasing first-pass and systemic clearance of susceptible substrates. In a landmark pharmacokinetic study published in the Lancet, Piscitelli et al. (N=8) showed that St. John's Wort reduced indinavir plasma AUC by 57% after 14 days of co-administration. While indinavir is not isotretinoin, both are CYP3A4 substrates, and the magnitude of enzyme induction demonstrated in that study established St. John's Wort as a clinically significant inducer (2).

Isotretinoin's metabolism involves CYP2C8, CYP3A4, and CYP26A1, as well as glucuronidation pathways. The CYP3A4 contribution is sufficient that induction by St. John's Wort is expected to reduce isotretinoin exposure, though the precise magnitude in humans has not been characterized in a dedicated clinical trial.

P-glycoprotein Induction

Beyond CYP3A4, hyperforin also induces P-glycoprotein (P-gp), an efflux transporter in the gut wall and blood-brain barrier. Increased P-gp activity reduces intestinal absorption of substrate drugs. Isotretinoin absorption is already highly variable and food-dependent (high-fat meals raise bioavailability by roughly 50%). Adding P-gp induction from St. John's Wort could decrease the fraction of an oral dose that reaches systemic circulation, stacking a second mechanism on top of the CYP3A4-mediated clearance increase (3).

Time Course of Induction

CYP3A4 induction is not immediate. Maximum induction typically develops over 7 to 14 days of consistent St. John's Wort use and persists for approximately 1 to 2 weeks after discontinuation. A patient who stops St. John's Wort on the day they start isotretinoin may still have residual induction for the first two weeks of treatment. This is clinically meaningful during the period when prescribers are assessing early response.

Isotretinoin Pharmacology: Why Exposure Matters

Isotretinoin's therapeutic and teratogenic effects are both concentration-dependent. The drug works by inducing apoptosis in sebaceous gland cells, dramatically reducing sebum production, and normalizing keratinocyte differentiation. Cumulative dose, typically targeted at 120 to 150 mg per kg of body weight over a course, is the strongest predictor of sustained remission (4).

Dose-Response Relationship

Studies comparing cumulative doses below 120 mg/kg to those above show relapse rates roughly doubling at lower cumulative exposures. A retrospective analysis published in the Journal of the American Academy of Dermatology found that patients who received less than 120 mg/kg had a relapse rate of approximately 38%, compared to 18% in those who reached or exceeded that threshold. If St. John's Wort reduces plasma AUC by even 20 to 30%, a patient taking a nominally adequate mg/kg dose may effectively be receiving sub-remission exposure (5).

Teratogenicity and iPLEDGE

The FDA label for isotretinoin carries its strongest contraindication against use in pregnancy. The drug causes major fetal malformations, including craniofacial, cardiac, thymic, and central nervous system defects, at therapeutic doses. The iPLEDGE program requires two concurrent forms of contraception for patients of childbearing potential (6).

St. John's Wort is a documented inducer of the CYP3A4 enzymes responsible for metabolizing ethinyl estradiol and progestins in hormonal contraceptives. Several case reports and a comprehensive review in Drug Safety documented breakthrough pregnancies in women taking combined oral contraceptives and St. John's Wort simultaneously (7). For a patient on isotretinoin who relies on hormonal contraception as one of their two iPLEDGE-required methods, adding St. John's Wort could theoretically compromise both the contraceptive and the isotretinoin concentration simultaneously. The compounded risk here is serious.

The iPLEDGE Program and Supplement Disclosure

IPLEDGE requires monthly interactions between patients, prescribers, and pharmacists. The program's educational materials do not currently enumerate St. John's Wort by name in patient-facing documentation, but the program's Risk Summary explicitly states: "Patients should inform their prescriber of all medications, vitamins, herbal products, and supplements they are taking."

The American Academy of Dermatology (AAD) clinical guidelines for isotretinoin state: "Prescribers should conduct a thorough medication reconciliation, including over-the-counter and herbal products, at each monthly visit." (8)

Despite this, real-world adherence to herbal supplement disclosure remains low, as the JAMA Internal Medicine data above illustrates.

What Happens If You Are Already Taking Both

If you are currently taking St. John's Wort and have started or are about to start isotretinoin, the appropriate step is to tell your prescriber before your next dose, not to stop either drug independently without guidance. Abruptly stopping St. John's Wort mid-course is not inherently dangerous, but it will reverse enzyme induction over 1 to 2 weeks, which could cause a rebound increase in isotretinoin plasma levels. In practice, that rebound is unlikely to reach toxic levels from standard isotretinoin doses, but your prescriber should know so they can monitor your clinical response and, if relevant, confirm your contraceptive status.

Do not substitute St. John's Wort with a prescription antidepressant on your own. If you were using St. John's Wort for mood support, discuss SSRI alternatives with your prescriber, as the isotretinoin label already requires mood monitoring.

Pharmacodynamic Considerations: Overlapping Effects on Mood

Beyond the pharmacokinetic interaction, there is a pharmacodynamic reason to think carefully about this combination. Isotretinoin's FDA label includes a warning about depression, psychosis, and rare cases of suicidal ideation. The mechanistic link between isotretinoin and mood changes remains debated, but the signal is present in post-marketing surveillance data and prompted mandatory label updates (9).

Why Patients Reach for St. John's Wort

Patients experiencing low mood, irritability, or anxiety during isotretinoin treatment sometimes self-medicate with St. John's Wort precisely because it is available without a prescription and carries a general reputation as a natural antidepressant. A Cochrane review of 27 trials (N=3,808) confirmed that St. John's Wort was more effective than placebo for mild-to-moderate depression and similarly effective to standard antidepressants, but with fewer side effects (10).

This creates a clinical paradox. The supplement has real efficacy for the condition the patient is trying to treat, but the mechanism by which it is taken alongside isotretinoin introduces meaningful pharmacokinetic risk. Prescribers should proactively screen for mood changes monthly and offer prescription alternatives if warranted, removing the temptation to self-medicate with a conflicting herbal product.

No Documented Serotonin Syndrome Risk

Unlike some drug-supplement pairings, the isotretinoin and St. John's Wort combination does not carry a recognized serotonergic interaction risk. St. John's Wort inhibits serotonin reuptake, and that property is relevant when combining it with SSRIs or SNRIs. Isotretinoin does not act on serotonin pathways, so serotonin syndrome is not a concern specific to this pairing.

Supplements Generally Considered Compatible with Isotretinoin

Avoiding St. John's Wort does not mean all supplements are off the table during isotretinoin therapy. The table below summarizes commonly asked-about options.

| Supplement | Interaction Risk with Isotretinoin | Notes | |---|---|---| | St. John's Wort | High (CYP3A4/P-gp induction) | Avoid | | Vitamin A (retinol) | High (additive retinoid toxicity) | Avoid; FDA label contraindication | | Vitamin D3 | Low | Generally safe; no known PK interaction | | Zinc sulfate | Low-to-moderate | May reduce isotretinoin absorption if taken simultaneously; separate by 2 hours | | Omega-3 fatty acids | Low | May reduce isotretinoin-associated hypertriglyceridemia | | Probiotics | Very low | No known interaction | | Magnesium | Very low | No known interaction |

Always disclose every supplement to your prescriber. The list above is not exhaustive, and formulation-specific excipients (e.g., high-dose vitamin E in some fish oil capsules) can introduce their own considerations.

Practical Guidance: What to Tell Your Dermatologist

Bring a complete supplement list to every monthly iPLEDGE visit. If you are taking St. John's Wort for mood or energy, flag this directly. Your dermatologist can:

1. Recommend discontinuing St. John's Wort before starting isotretinoin, allowing at least 2 weeks for enzyme induction to resolve.
2. Refer you to a psychiatrist or primary care provider for a prescription-grade mood support option that does not interfere with CYP3A4.
3. Document the disclosure in your iPLEDGE record, which protects both you and the prescriber.

If you use hormonal contraception as one of your two required iPLEDGE birth control methods, stopping St. John's Wort is especially important. The Drug Safety review by Hall et al. Documented seven case reports of unintended pregnancy during combined oral contraceptive and St. John's Wort co-use, underscoring that the induction effect is not theoretical (7).

Frequently Asked Questions